InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: antihama post# 2494

Monday, 01/28/2019 4:44:00 PM

Monday, January 28, 2019 4:44:00 PM

Post# of 3283
I agree. I was thinking possible toxicity also.

But, why did SPPI say: for "strategic reasons"?

Pozi + T-DM1 for mBC was way off in the future as far as I understand.

If Pozi + T-DM1 has a toxicity issue in mBC, that may also be a problem in NSCLC.

My guess is they want to focus on Bevacizumab + Pozi for exon20 NSCLC.